The CDC has issued recommendations for the use of anti-viral medications in patients with influenza this year, due to the high resistance of Influenza A (H1N1) to oseltamivir. Of the few Influenza A (H1N1) strains tested this year, 98% were resistant to oseltamivir (but all were susceptible to zanamivir, amantadine, and rimantadine) (CDC site). They recommend avoiding oseltamivir in patients with Influenza A (unless local surveillance suggests the dominant Influenza A strain is H3N2, and not H1N1). Oseltamivir can still be used for Influenza A (H3N2) or Influenza B. Amantadine and rimantadine have no activity against Influenza B, and are generally ineffective against Influenza A (H3N2). In summary, Influenza A (H1N1) can be treated with zanamivir, amantadine or rimantadine; Influenza A (H3N2) can be treated with zanamivir or oseltamivir; Influenza B can be treated with zanamivir or oseltamivir.
by Deepak Asudani, MD, MPH, FHM Whether it is the prompt and expeditious international collaboration to develop an Ebola vaccine, or tardy but promising development of the first anti parasitic malarial vaccine or the fascinating technology utilizing synthetic DNA for vaccine development against MERS, these developments promise to highlight significant strides in vaccine development for […]
Economists describe preferences in two ways: revealed and stated. Say, for example, I asked you to implement a penalty program for your team with the goal of decreasing the number of occasions members did not clean their hands after a patient encounter. Because you know bad hands equal bad outcomes, you’re apt to offer up […]
by Eric Howell, MD, SFHM “Tell me what you know about antibiotics.” That’s the discussion I start with hospitalized patients all the time, right after they ask me to prescribe antibiotics for their simple cough, or other viral-like illness. And, from their perspective, asking for antibiotics makes sense. After all, antibiotics have been the physician’s […]